In Omni MedSci, Inc. v. Apple Inc., ___ F.4th ___, Nos. 2020-1715, -1716 (Fed. Cir. Aug. 2, 2021), the U.S. Court of Appeals for the Federal Circuit held that the University of Michigan’s technology…
Patent asserted against Apple and Samsung merely claimed the abstract idea of taking two pictures and using those pictures to enhance each other in some way.
A district court’s dismissal of…
Plaintiff’s arguments before the district court were often objectively unreasonable or frivolous; the frivolous nature of his appeal also warranted sanctions against plaintiff and his counsel of…
Biologic drugs, many of which are antibodies, represent an increasing share of the pharmaceutical market. In recent years, numerous broad functional patent claims directed at therapeutic antibodies…
Today (20 January 2021) seems to be a perfect day to celebrate democracy and the rule of law.
I will therefore not keep you up for too long, but just wanted to make a short personal comment and a…
St. Jude Medical failed to show that challenged claims of patent owned by Snyders had been anticipated by other patents, nor did it prove that a particular combination demonstrated obviousness.…
PTAB did not err in its claim construction or obviousness findings in two IPRs filed by Westinghouse that challenged two Siemens patents.
Substantial evidence supported two Patent Trial and Appeal…
In Immunex Corp. et al. v. Sandoz Inc. et al., the Federal Circuit found that there was no obviousness-type double patenting because there was no “common ownership” of patents under an agreement…
Declarations from generic drug makers alleged only possible future injury from implementation of the 2019 law that created a presumption that so-called "pay for delay" settlement agreements are…
The PTAB did not err in finding that airplane interior designers would have been motivated to combine prior art to arrive at the space-saving configuration disclosed by the challenged patents.…
